The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide
Open accessAbstract
Advanced-stage peritoneal carcinomatosis is resistant to current chemotherapy treatment and, in the case of metastatic ovarian cancer, results in a devastating 15%-20% survival rate. Therapeutics that restore genes inactivated during oncogenesis are predicted to be more potent and specific than current therapies. Experiments with viral vectors have demonstrated the theoretical utility of expressing the p53 tumor suppressor gene in cancer cells. However, clinically useful alternative approaches for introducing p53 activity into cancer cells are clearly needed. It has been hypothesized that direct reactivation of endogenous p53 protein in cancer cells will be therapeutically beneficial, but few tests of this hypothesis have been carried out in vivo. We report that a transducible D-isomer RI-TATp53C' peptide activates the p53 protein in cancer cells, but not normal cells. RI-TATp53C' peptide treatment of preclinical terminal peritoneal carcinomatosis and peritoneal lymphoma models results in significant increases in lifespan (greater than 6-fold) and the generation of disease-free animals. These proof-of-concept observations show that specific activation of endogenous p53 activity by a macromolecular agent is therapeutically effective in preclinical models of terminal human malignancy. Our results suggest that TAT-mediated transduction may be a useful strategy for the therapeutic delivery of large tumor suppressor molecules to malignant cells in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686 · cited 3×
“Most patients who succumb to cancer do so not from primary tumor burden, but from metastatic disease (Fidler 2003).”
BackgroundRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Wadia, J. S., Stan, R. V., & Dowdy, S. F. (2004) · Nature Medicine · doi:10.1038/nm996 · Cited by 1,647
Self-citationRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Cited by
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Cell-Penetrating Peptides: From Basic Research to Clinics
Guidotti, G., Brambilla, L., & Rossi, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.003 · Cited by 1,147
Cell-Penetrating Peptides: Design, Synthesis, and Applications
Copolovici, D. M., Langel, K., Eriste, E., & Langel, Ü. (2014) · ACS Nano · doi:10.1021/nn4057269 · Cited by 963
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics
Heitz, F., Morris, M. C., & Divita, G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00057.x · Cited by 867
The genetics of the p53 pathway, apoptosis and cancer therapy
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 676
Cationic TAT peptide transduction domain enters cells by macropinocytosis
Kaplan, I. M., Wadia, J. S., & Dowdy, S. F. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.018 · Cited by 668
Self-citationWADIA, J., & DOWDY, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.005 · Cited by 428
Self-citationCell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives
Patel, L. N., Zaro, J. L., & Shen, W.-C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9303-7 · Cited by 425
FLIP-mediated autophagy regulation in cell death control
Lee, J.-S., Li, Q., Lee, J.-Y., Lee, S.-H., Jeong, J. H., Lee, H.-R., Chang, H., Zhou, F.-C., Gao, S.-J., Liang, C., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1980 · Cited by 406
Characterisation of cell‐penetrating peptide‐mediated peptide delivery
Jones, S. W., Christison, R., Bundell, K., Voyce, C. J., Brockbank, S. M. V., Newham, P., & Lindsay, M. A. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706279 · Cited by 385
TAT transduction: the molecular mechanism and therapeutic prospects
Gump, J. M., & Dowdy, S. F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.002 · Cited by 356
Self-citationKristensen, M., Birch, D., & Mørck Nielsen, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020185 · Cited by 304
The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
J. Boohaker, R., W. Lee, M., Vishnubhotla, P., M. Perez, J. L., & R. Khaled, A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801661004 · Cited by 302
Reissmann, S. (2014) · Journal of Peptide Science · doi:10.1002/psc.2672 · Cited by 266
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics
Lucana, M. C., Arruga, Y., Petrachi, E., Roig, A., Lucchi, R., & Oller-Salvia, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122065 · Cited by 102
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
Unlocking the Potential of Retro-Inverso (RI) Peptides as Future Drug Candidates
Al Musaimi, O. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10639-1 · Cited by 18
Metadata
- Authors
- Snyder, E. L., Meade, B. R., Saenz, C. C., & Dowdy, S. F.
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2004-02-17
- Volume
- 2
- Issue
- 2
- Pages
- e36
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- OpenAlex
- W2090471601
- Cited by
- 199
- References
- 4
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.